Impact of resistance exercise on patients with chronic kidney disease

BMC Nephrology

Table 3 The outcomes of pooled WMDs of meta-analysis

Overall	N	n (I/C)	WMD	95%CI	P (H)	I²	P
GFR (ml/(min•1.73m²))	7	191/185	1.82	-0.59 ~ 4.23	0.002	71.8%	0.139
CRP (mg/L)	9	202/187	-2.46	-4.21 ~ -0.72	0.000	75.9%	0.006
Serum creatinine (mg/dL)	5	93/89	-0.01	-0.17 ~ 0.14	0.137	42.7%	0.849
Hemoglobin (g/dL)	5	67/74	-0.07	-0.62 ~ 0.47	0.260	24.1%	0.787
HBA1c (%)	3	75/74	-0.46	-0.63 ~ -0.29	0.100	56.6%	0.000
HDL (mg/dL)	6	167/161	2.24	-2.54 ~ 7.02	0.004	71.0%	0.359
LDL (mg/dL)	6	165/159	1.72	0.07 ~ 3.36	0.512	0.0%	0.040
6-min walk (m)	2	52/51	89.93	50.12 ~ 129.74	0.136	55.0%	0.000
BMI (kg/m²)	8	175/162	0.09	-0.52 ~ 0.70	0.411	2.4%	0.776
Fat-free mass (kg)	2	46/45	6.53	1.14 ~ 11.93	0.013	83.6%	0.018
Fat mass (kg)	2	46/45	-5.38	-13.29 ~ 2.53	0.008	85.8%	0.183
Grip strength (kgf)	7	159/160	3.97	1.89 ~ 6.05	0.032	56.5%	0.000

N: number of included studies; n (I/C): number of patients of intervention (resistance exercise) group and control group (I for intervention group; C for control group); WMD: weighted mean difference; P (H): p value for heterogeneity; P: p value for pooled WMD effect; GFR: glomerular filtration rate; CRP: C-reactive protein; HBA1c: glycosylated hemoglobin, type A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; BMI: body mass index

ISSN: 1471-2369